Table 1 Summary of miRNA expression studies on samples from prostate cancer patients
From: miRNAs associated with prostate cancer risk and progression
Author year (reference) | Tissue/serum | Outcome | miRNA identified |
|---|---|---|---|
Risk/Diagnostic | |||
 Ozen, 2008 [79] | Tissue | Risk/Diagnostic | Let-7b-g, 26a-b, 29a-c, 30a-e, 99a-b, 125a-b |
 Gandellini, 2009 [78] | Tissue | Risk/Diagnostic | miR-205 |
 Mahn 2011 [118] | Tissue/Serum | Diagnostic | let7i, 16, 26a, 195 |
 Wach, 2012 [10] | Tissue | Diagnostic | miR-143, 145, 375 |
 Avgeris, 2013 [101] | Tissue | Diagnostic | miR-145 |
 Srivastava, 2013 [105] | Tissue/Urine | Diagnostic | miR-205, 221, 99b |
 Tsuchiyama, 2013 [106] | Tissue | Diagnostic | miR-182-5p |
 Guzel 2015 [107] | Tissue | Diagnostic | miR-361-3p, 133b, 221, 203 |
 Roberts, 2015 [128] | Tissue/Serum | Diagnostic | miR-200b, 200c, 375 |
 Kristensen 2016 [112] | Tissue | Diagnostic | Up: miR-375, 663b, 615-3p, 425-5p, 663a, 182-5p, 183-5p. Down: miR-205-5p, 221-3p, 222-3p, 376c-3p, 136-5p, 455-3p, 455-5p, −154-5p |
 Mitchell, 2008 [35] | Serum | Diagnostic | miR-141 |
 Lodes, 2009 [137] | Serum | Diagnostic | miR-16, 92a, 103, 107 |
 Moltzahn, 2011 [99] | Serum | Diagnostic | miR-26b, 223, 874, 1274a |
 Yaman Agaoglu, 2011 [54] | Plasma | Diagnostic | miR-21, 141, 221 |
 Selth, 2012 [114] | Serum | Diagnostic | miR-141, 298, 346, 375 |
 Chen 2012 [119] | Plasma | Diagnostic | let7c, let7e, 30c, 622, 1285 |
 Cheng, 2013 [120] | Serum | Diagnostic | miR-210 |
 Haldrup, 2014 [113] | Serum | Diagnostic | miR-141, 375 |
 Westermann, 2014 [121] | Serum | Diagnostic | miR-141 |
 Kachakova, 2015 [122] | Plasma | Diagnostic | let-7c, 375 |
 Haj-Ahmad, 2014 [126] | Urine | Diagnostic | miR-182-5, 484 |
 Korzeniewski, 2014 [127] | Urine | Diagnostic | miR-483-5p, 1275, 1290 |
Risk/Progression | |||
 Porkka, 2007 [87] | Tissue | Risk/Progression | Let-7a-d, Let-7f, 19b, 145, 184, 198, 202, 210, |
 Ambs, 2008 [40] | Tissue | Risk/Progression | miR-1, 32, 101, 106b, 182, 200a, 200b, 494, 520 h |
 Mercatelli, 2008 [42] | Tissue | Progression | miR-221, 222 |
 Prueitt, 2008 [80] | Tissue | Progression | miR-2, 10, 125b, 224 |
 Tong, 2009 [76] | Tissue | Risk/Progression | miR-23b, 100, 135b, 145, 194, 221, 222 |
 Wang, 2009 [90] | Tissue | Progression | miR-9*, 16, 221, 222, 331-3p, 145, 551a |
 Szczyrba, 2010 [61] | Tissue | Progression | miR-143 |
 Shaefer, 2010 [81] | Tissue | Risk/Progression | miR-96, 205 |
 Pesta, 2010 [93] | Tissue | Progression | miR-20a |
 Khan, 2010 [88] | Tissue | Progression | miR-128 |
 Spahn, 2010 [91] | Tissue | Progression | miR-221 |
 Hagman, 2010 [92] | Tissue | Risk/Progression | miR-34c |
 Brase, 2011 [115] | Tissue/Serum | Progression | miR-141, 375 |
 Barnabas, 2011 [103] | Tissue | Progression | miR-151 |
 Leite, 2011 [138] | Tissue | Progression | let7c, miR-100, miR-145, miR-191 |
 Martens-Uzunova, 2012 [48] | Tissue | Progression | miR-1, 133a, 133b, 143, 143*, 145, 145*, 204, 221, 222 |
 Li, 2012 [55] | Tissue | Progression | miR-21 |
 Tsuchiyama, 2013 [106] | Tissue | Progression | miR-182-5p |
 Amankwah, 2013 [102] | Tissue | Progression | miR-21 |
 He, 2013 [134] | Tissue | Progression | miR-19a, miR-374b |
 Kristensen, 2014 [89] | Tissue | Progression | miR-224, 452 |
 Wang, 2014 [124] | Tissue/Serum | Progression | miR-19, miR-345, miR-519c-5p |
 Dip, 2015 [139] | Tissue | Progression | Let-7c |
 Zhang, 2011 [100] | Serum | Progression | miR-21 |
 Yaman Agaoglu, 2011 [54] | Plasma | Progression | miR-21, miR-221 |
 Shen, 2012 [56] | Plasma | Progression | miR-20a, miR-21, miR-145, miR-221 |
 Watahiki, 2013 [123] | Plasma | Progression | miR-21, −126, −141, −151-3p, −152, −200c,-375, −423-3p |
 Nguyen, 2013 [116] | Serum | Progression | miR-141, miR-375, miR-378, miR-409-3p |
Diagnostic/Progression | |||
 Hao, 2011 [95] | Tissue | Diagnostic/Progression | miR-21 |
 Mihelich, 2011 [98] | Tissue | Diagnostic/Progression | miR-96, miR-182, miR-183 |
 Bryant 2012 [117] | Serum/Urine | Diagnostic/Progression | miR-181a-2, miR-625, miR-107, miR-574-3p, miR-20a, miR-23a, miR-624 |
 Mavridis, 2013 [109] | Tissue | Diagnostic/Progression | miR-224 |
 Larne, 2013 [108] | Tissue | Diagnostic/Progression | miR-96-5p, miR-183-5p, miR-145-5p, miR-221-5p |
 Walter, 2013 [110] | Tissue | Diagnostic/Progression | Up: miR-122, miR-335, miR-184, miR-193, miR-34, miR-138, Down: miR-373, −9, −198, −144 -215, −96, −222, −148, −92, −27, −125, −126, −27 |
 Casanova-Salas, 2014 [111] | Tissue/Serum | Diagnostic/Progression | miR-187 and miR-182 |
 Mihelich, 2015 [125] | Serum | Diagnostic/Progression | let-7a, −24, −26b, −30c, −93, −100, −103, −106a, −107, −130b, −146a, −223, −451, −874, |
 Kristensen, 2016 [112] | Tissue | Diagnostic/Progression | miR185-5p, miR-221-3p, miR-326 |
Treatment response | |||
 He, 2013 [134] | Tissue | Treatment Response | miR-23b, miR-220, miR-221, miR-222, and miR-205 |
 Lichner, 2013 [135] | Tissue | Treatment Response | miR-152 |
 Gonzales, 2011 [133] | Plasma | Treatment Response | miR-141 |
 Cheng, 2013 [120] | Serum | Treatment Response | miR-210 |
 Someya, 2015 [136] | Blood | Treatment Response | miR-99a |